PT  - JOURNAL ARTICLE
AU  - Tang, Shaohua
AU  - Sun, Rui
AU  - Xiao, Qi
AU  - Mao, Tingting
AU  - Ge, Weigang
AU  - Huang, Chongquan
AU  - Luo, Meng
AU  - Qian, Liujia
AU  - Chen, Hao
AU  - Zhang, Qiushi
AU  - Li, Sainan
AU  - Liu, Wei
AU  - Li, Shufei
AU  - Xu, Xueqin
AU  - Li, Huanzheng
AU  - Wu, Lianpeng
AU  - Dai, Jianyi
AU  - Gao, Huanhuan
AU  - Li, Lu
AU  - Lu, Tian
AU  - Liang, Xiao
AU  - Cai, Xue
AU  - Ruan, Guan
AU  - Liu, Kexin
AU  - Xu, Fei
AU  - Li, Yan
AU  - Zhu, Yi
AU  - Huang, Jianping
AU  - Guo, Tiannan
TI  - Proteomics Uncovers Immunosuppression in COVID-19 Patients with Long Disease Course
AID  - 10.1101/2020.06.14.20131078
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.14.20131078
4099  - http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131078.short
4100  - http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131078.full
AB  - Little is known regarding why a subset of COVID-19 patients exhibited prolonged positivity of SARS-CoV-2 infection. Here, we present a longitudinal sera proteomic resource for 37 COVID-19 patients over nine weeks, in which 2700 proteins were quantified with high quality. Remarkably, we found that during the first three weeks since disease onset, while clinical symptoms and outcome were indistinguishable, patients with prolonged disease course displayed characteristic immunological responses including enhanced Natural Killer (NK) cell-mediated innate immunity and regulatory T cell-mediated immunosuppression. We further showed that it is possible to predict the length of disease course using machine learning based on blood protein levels during the first three weeks. Validation in an independent cohort achieved an accuracy of 82%. In summary, this study presents a rich serum proteomic resource to understand host responses in COVID-19 patients and identifies characteristic Treg-mediated immunosuppression in LC patients, nominating new therapeutic target and diagnosis strategy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000031699Funding StatementThis work is supported by grants from Tencent Foundation (2020), National Natural Science Foundation of China (81972492, 21904107, 81672086), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), and Hangzhou Agriculture and Society Advancement Program (20190101A04).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Ethical/Institutional Review Board of Wenzhou Central Hospital and Westlake University. Contents from patients were waived by the boardsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material. The proteomics data are deposited in ProteomeXchange Consortium (https://www.iprox.org/). Project ID: IPX0002170000. https://www.iprox.org/